Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma

Ana Maria Florea, Elizabeth Varghese, Jennifer E. McCallum, Safa Mahgoub, Irfan Helmy, Sharon Varghese, Neha Gopinath, Steffen Sass, Fabian J. Theis, Guido Reifenberger, Dietrich Busselberg

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Neuroblastoma (NB) is a pediatric cancer treated with poly-chemotherapy including platinum complexes (e.g. cisplatin (CDDP), carboplatin), DNA alkylating agents, and topoisomerase I inhibitors (e.g. topotecan (TOPO)). Despite aggressive treatment, NB may become resistant to chemotherapy. We investigated whether CDDP and TOPO treatment of NB cells interacts with the expression and function of proteins involved in regulating calcium signaling. Human neuroblastoma cell lines SH-SY5Y, IMR-32 and NLF were used to investigate the effects of CDDP and TOPO on cell viability, apoptosis, calcium homeostasis, and expression of selected proteins regulating intracellular calcium concentration ([Ca2+]i). In addition, the impact of pharmacological inhibition of [Ca2+]i-regulating proteins on neuroblastoma cell survival was studied. Treatment of neuroblastoma cells with increasing concentrations of CDDP (0.1-10 μM) or TOPO (0.1 nM-1 μM) induced cytotoxicity and increased apoptosis in a concentration- and time-dependent manner. Both drugs increased [Ca2+]i over time. Treatment with CDDP or TOPO also modified mRNA expression of selected genes encoding [Ca2+]i-regulating proteins. Differentially regulated genes included S100A6, ITPR1, ITPR3, RYR1 and RYR3. With FACS and confocal laser scanning microscopy experiments we validated their differential expression at the protein level. Importantly, treatment of neuroblastoma cells with pharmacological modulators of [Ca2+]i-regulating proteins in combination with CDDP or TOPO increased cytotoxicity. Thus, our results confirm an important role of calcium signaling in the response of neuroblastoma cells to chemotherapy and suggest [Ca2+]i modulation as a promising strategy for adjunctive treatment.

Original languageEnglish
Pages (from-to)22876-22893
Number of pages18
JournalOncotarget
Volume8
Issue number14
DOIs
Publication statusPublished - 2017

Fingerprint

Topotecan
Neuroblastoma
Calcium
Drug Therapy
Proteins
Calcium Signaling
Cell Survival
Therapeutics
Pharmacology
Topoisomerase I Inhibitors
Apoptosis
Alkylating Agents
Carboplatin
Platinum
Confocal Microscopy
Cisplatin
Homeostasis
Pediatrics
Gene Expression
Cell Line

Keywords

  • Calcium signaling
  • Chemotherapy
  • Cisplatin
  • Neuroblastoma
  • Topotecan

ASJC Scopus subject areas

  • Oncology

Cite this

Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma. / Florea, Ana Maria; Varghese, Elizabeth; McCallum, Jennifer E.; Mahgoub, Safa; Helmy, Irfan; Varghese, Sharon; Gopinath, Neha; Sass, Steffen; Theis, Fabian J.; Reifenberger, Guido; Busselberg, Dietrich.

In: Oncotarget, Vol. 8, No. 14, 2017, p. 22876-22893.

Research output: Contribution to journalArticle

Florea, AM, Varghese, E, McCallum, JE, Mahgoub, S, Helmy, I, Varghese, S, Gopinath, N, Sass, S, Theis, FJ, Reifenberger, G & Busselberg, D 2017, 'Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma', Oncotarget, vol. 8, no. 14, pp. 22876-22893. https://doi.org/10.18632/oncotarget.15283
Florea, Ana Maria ; Varghese, Elizabeth ; McCallum, Jennifer E. ; Mahgoub, Safa ; Helmy, Irfan ; Varghese, Sharon ; Gopinath, Neha ; Sass, Steffen ; Theis, Fabian J. ; Reifenberger, Guido ; Busselberg, Dietrich. / Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma. In: Oncotarget. 2017 ; Vol. 8, No. 14. pp. 22876-22893.
@article{99703fe845a44eac9543ba4486533400,
title = "Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma",
abstract = "Neuroblastoma (NB) is a pediatric cancer treated with poly-chemotherapy including platinum complexes (e.g. cisplatin (CDDP), carboplatin), DNA alkylating agents, and topoisomerase I inhibitors (e.g. topotecan (TOPO)). Despite aggressive treatment, NB may become resistant to chemotherapy. We investigated whether CDDP and TOPO treatment of NB cells interacts with the expression and function of proteins involved in regulating calcium signaling. Human neuroblastoma cell lines SH-SY5Y, IMR-32 and NLF were used to investigate the effects of CDDP and TOPO on cell viability, apoptosis, calcium homeostasis, and expression of selected proteins regulating intracellular calcium concentration ([Ca2+]i). In addition, the impact of pharmacological inhibition of [Ca2+]i-regulating proteins on neuroblastoma cell survival was studied. Treatment of neuroblastoma cells with increasing concentrations of CDDP (0.1-10 μM) or TOPO (0.1 nM-1 μM) induced cytotoxicity and increased apoptosis in a concentration- and time-dependent manner. Both drugs increased [Ca2+]i over time. Treatment with CDDP or TOPO also modified mRNA expression of selected genes encoding [Ca2+]i-regulating proteins. Differentially regulated genes included S100A6, ITPR1, ITPR3, RYR1 and RYR3. With FACS and confocal laser scanning microscopy experiments we validated their differential expression at the protein level. Importantly, treatment of neuroblastoma cells with pharmacological modulators of [Ca2+]i-regulating proteins in combination with CDDP or TOPO increased cytotoxicity. Thus, our results confirm an important role of calcium signaling in the response of neuroblastoma cells to chemotherapy and suggest [Ca2+]i modulation as a promising strategy for adjunctive treatment.",
keywords = "Calcium signaling, Chemotherapy, Cisplatin, Neuroblastoma, Topotecan",
author = "Florea, {Ana Maria} and Elizabeth Varghese and McCallum, {Jennifer E.} and Safa Mahgoub and Irfan Helmy and Sharon Varghese and Neha Gopinath and Steffen Sass and Theis, {Fabian J.} and Guido Reifenberger and Dietrich Busselberg",
year = "2017",
doi = "10.18632/oncotarget.15283",
language = "English",
volume = "8",
pages = "22876--22893",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "14",

}

TY - JOUR

T1 - Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma

AU - Florea, Ana Maria

AU - Varghese, Elizabeth

AU - McCallum, Jennifer E.

AU - Mahgoub, Safa

AU - Helmy, Irfan

AU - Varghese, Sharon

AU - Gopinath, Neha

AU - Sass, Steffen

AU - Theis, Fabian J.

AU - Reifenberger, Guido

AU - Busselberg, Dietrich

PY - 2017

Y1 - 2017

N2 - Neuroblastoma (NB) is a pediatric cancer treated with poly-chemotherapy including platinum complexes (e.g. cisplatin (CDDP), carboplatin), DNA alkylating agents, and topoisomerase I inhibitors (e.g. topotecan (TOPO)). Despite aggressive treatment, NB may become resistant to chemotherapy. We investigated whether CDDP and TOPO treatment of NB cells interacts with the expression and function of proteins involved in regulating calcium signaling. Human neuroblastoma cell lines SH-SY5Y, IMR-32 and NLF were used to investigate the effects of CDDP and TOPO on cell viability, apoptosis, calcium homeostasis, and expression of selected proteins regulating intracellular calcium concentration ([Ca2+]i). In addition, the impact of pharmacological inhibition of [Ca2+]i-regulating proteins on neuroblastoma cell survival was studied. Treatment of neuroblastoma cells with increasing concentrations of CDDP (0.1-10 μM) or TOPO (0.1 nM-1 μM) induced cytotoxicity and increased apoptosis in a concentration- and time-dependent manner. Both drugs increased [Ca2+]i over time. Treatment with CDDP or TOPO also modified mRNA expression of selected genes encoding [Ca2+]i-regulating proteins. Differentially regulated genes included S100A6, ITPR1, ITPR3, RYR1 and RYR3. With FACS and confocal laser scanning microscopy experiments we validated their differential expression at the protein level. Importantly, treatment of neuroblastoma cells with pharmacological modulators of [Ca2+]i-regulating proteins in combination with CDDP or TOPO increased cytotoxicity. Thus, our results confirm an important role of calcium signaling in the response of neuroblastoma cells to chemotherapy and suggest [Ca2+]i modulation as a promising strategy for adjunctive treatment.

AB - Neuroblastoma (NB) is a pediatric cancer treated with poly-chemotherapy including platinum complexes (e.g. cisplatin (CDDP), carboplatin), DNA alkylating agents, and topoisomerase I inhibitors (e.g. topotecan (TOPO)). Despite aggressive treatment, NB may become resistant to chemotherapy. We investigated whether CDDP and TOPO treatment of NB cells interacts with the expression and function of proteins involved in regulating calcium signaling. Human neuroblastoma cell lines SH-SY5Y, IMR-32 and NLF were used to investigate the effects of CDDP and TOPO on cell viability, apoptosis, calcium homeostasis, and expression of selected proteins regulating intracellular calcium concentration ([Ca2+]i). In addition, the impact of pharmacological inhibition of [Ca2+]i-regulating proteins on neuroblastoma cell survival was studied. Treatment of neuroblastoma cells with increasing concentrations of CDDP (0.1-10 μM) or TOPO (0.1 nM-1 μM) induced cytotoxicity and increased apoptosis in a concentration- and time-dependent manner. Both drugs increased [Ca2+]i over time. Treatment with CDDP or TOPO also modified mRNA expression of selected genes encoding [Ca2+]i-regulating proteins. Differentially regulated genes included S100A6, ITPR1, ITPR3, RYR1 and RYR3. With FACS and confocal laser scanning microscopy experiments we validated their differential expression at the protein level. Importantly, treatment of neuroblastoma cells with pharmacological modulators of [Ca2+]i-regulating proteins in combination with CDDP or TOPO increased cytotoxicity. Thus, our results confirm an important role of calcium signaling in the response of neuroblastoma cells to chemotherapy and suggest [Ca2+]i modulation as a promising strategy for adjunctive treatment.

KW - Calcium signaling

KW - Chemotherapy

KW - Cisplatin

KW - Neuroblastoma

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=85016948961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016948961&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.15283

DO - 10.18632/oncotarget.15283

M3 - Article

AN - SCOPUS:85016948961

VL - 8

SP - 22876

EP - 22893

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 14

ER -